三个皮匠报告—— 严选型全行业研究报告分享下载平台,您的专属行业智库!
欢迎来到三个皮匠报告!
登录
帮助中心
首页
最新
研搜
BETA
合集
英文
会议
数据
财报库
政策库
自研报告
入驻
您的当前位置:
首页
>
行业数据
>
美国肥胖/T2DM/动脉粥样硬化心血管病/慢性肾
美国肥胖/T2DM/动脉粥样硬化心血管病/慢性肾
行业数据
下载Excel
下载图片
原图定位
图片属性
图片格式:PNG
图片大小:574KB
图片尺寸:1169*1000
同报告图片
/
4
PHxiZWdpbl9vZl9ib3h8PiMjIyDnvo7lm73ogqXog5YvVDJETS/liqjohInnsqXmoLfnoazljJblv4PooYDnrqHnl4Uv5oWi5oCn6IK+55eF562J55a+55eF5Lq6576k5pWw5o2u6KGoCgp8IOeWvueXheexu+WIqyAgICAgICAgICAgICAgICAgICAgIHwg5aSn6Ie05Lq65pWw77yI55m+5LiH77yJIHwKfC0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS0tLS0tLS18Cnwg6IKl6IOW77yIT2Jlc2l0ee+8iSAgICAgICAgICAgICAgfCB+MTE1ICAgICAgICAgICAgIHwKfCAy5Z6L57OW5bC/55eF77yIVHlwZSAyIGRpYWJldGVz77yJIHwgfjM1ICAgICAgICAgICAgICB8Cnwg5Yqo6ISJ57Kl5qC356Gs5YyW5oCn5b+D6KGA566h55eF77yIQVNDVkTvvIkgfCB+MjEgICAgICAgICAgICAgIHwKfCDmhaLmgKfogr7nl4XvvIhDS0QsIHN0YWdlIDMr77yJICAgIHwgfjE3ICAgICAgICAgICAgICB8Cgp8IOmHjeWPoOWMuuWfnyAgICAgICAgICAgICAgICAgICAgIHwg5Lq65pWw77yI55m+5LiH77yJICAgICB8CnwtLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tLS0tLS0tfAp8IOS7heiCpeiDliAgICAgICAgICAgICAgICAgICAgICAgfCA4NCAgICAgICAgICAgICAgIHwKfCDogqXog5YgKyDliqjohInnsqXmoLfnoazljJbmgKflv4PooYDnrqHnl4UgfCA1ICAgICAgICAgICAgICAgIHwKfCDogqXog5YgKyAy5Z6L57OW5bC/55eFICAgICAgICAgICAgIHwgMTUgICAgICAgICAgICAgICB8Cnwg6IKl6IOWICsg5Yqo6ISJ57Kl5qC356Gs5YyW5oCn5b+D6KGA566h55eFICsgMuWei+ezluWwv+eXhSB8IDQgICAgICAgICAgICAgICAgfAp8IOiCpeiDliArIDLlnovns5blsL/nl4UgKyDmhaLmgKfogr7nl4UgICB8IDIgICAgICAgICAgICAgICAgfAp8IOiCpeiDliArIOWKqOiEieeypeagt+ehrOWMluaAp+W/g+ihgOeuoeeXhSArIOaFouaAp+iCvueXhSB8IDIgICAgICAgICAgICAgICAgfAp8IOiCpeiDliArIOWKqOiEieeypeagt+ehrOWMluaAp+W/g+ihgOeuoeeXhSArIDLlnovns5blsL/nl4UgKyDmhaLmgKfogr7nl4UgfCAxICAgICAgICAgICAgICAgIHwKfCDku4Uy5Z6L57OW5bC/55eFICAgICAgICAgICAgICAgICAgfCA5ICAgICAgICAgICAgICAgIHwKfCAy5Z6L57OW5bC/55eFICsg5oWi5oCn6IK+55eFICAgICAgICAgfCAxICAgICAgICAgICAgICAgIHwKfCAy5Z6L57OW5bC/55eFICsg5Yqo6ISJ57Kl5qC356Gs5YyW5oCn5b+D6KGA566h55eFICsg5oWi5oCn6IK+55eFIHwgMyAgICAgICAgICAgICAgICB8Cnwg5LuF5Yqo6ISJ57Kl5qC356Gs5YyW5oCn5b+D6KGA566h55eFICAgICB8IDUgICAgICAgICAgICAgICAgfAp8IOWKqOiEieeypeagt+ehrOWMluaAp+W/g+ihgOeuoeeXhSArIOaFouaAp+iCvueXhSB8IDEgICAgICAgICAgICAgICAgfAp8IOS7heaFouaAp+iCvueXhSAgICAgICAgICAgICAgICAgICB8IDYgICAgICAgICAgICAgICAgfAoKCui1hOaWmeadpea6kO+8muivuuWSjOivuuW+t++8jOWbvemHkeivgeWIuOeglOeptuaJgDx8ZW5kX29mX2JveHw+
所属报告:
【国金证券】医药行业研究:GLP-1专题,产品迭代驱动市场扩容,关注靶点、剂型及联合疗法研发进展-251117(38页).pdf
打包全文图表
相关数据
APOC3及其在动脉粥样硬化中的潜在机制
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
收藏
行业数据
2026-03-06
原图定位
查看详情
ACHIEVE-3(全球I川期):1,698例接受二甲双胍治疗但血糖控制不佳的T2DM成年患者
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
收藏
行业数据
2026-01-12
原图定位
查看详情
ATTAIN-1(全球I川期):3,127例肥胖或超重且合并体重相关并发症(不含T2DM)的成年患者
收藏
行业数据
2026-01-12
原图定位
查看详情
国家心血管病中心发布的《中国心血管健康与疾病报告2024》
fCDkurrnvqTnibnlvoEgICAgICAgICAgICAgICAgICAgICB8IOW/g+ihgOeuoeaCo+eXhemjjumZqSB8CnwtLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tLS0tLXwKfCDnlLfmgKfvvJw1NeWygeOAgeWls+aAp++8nDY15bKB55qE5pep5Y+R5a625peP5Y+y5Lq6576kIHwgMiAtIDPlgI0gICAgICAgIHwKCui1hOaWmeadpea6kO+8muWbveWutuW/g+ihgOeuoeeXheS4reW/g+WPkeW4g+eahOOAiuS4reWbveW/g+ihgOeuoeWBpeW6t+S4jueWvueXheaKpeWRijIwMjTjgIs=
收藏
行业数据
2025-12-25
原图定位
查看详情
1型糖尿病(T1DM)和2型糖尿病(T2DM)的鉴别要点
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
收藏
行业数据
2025-11-25
原图定位
查看详情
2008年美国FDA对制药行业的监管规定,针对二型糖尿病类药物需要进行心血管结局研究
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
收藏
行业数据
2025-11-20
原图定位
查看详情
美国肥胖/T2DM/Mash等疾病人群韦恩
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
收藏
行业数据
2025-11-19
原图定位
查看详情
T2DM药物在美国、中国和欧洲市场的规模
PHxiZWdpbl9vZl9ib3h8PiMjIyBUMkRN6I2v54mp5biC5Zy66KeE5qih55qE6KGo5qC877yI5Y2V5L2N77ya5Y2B5Lq/576O5YWD77yJCgp8IOW5tOS7vSAgIHwg5Lit5Zu9IHwg576O5Zu9IHwg5qyn5rSyIHwKfC0tLS0tLS0tfC0tLS0tLXwtLS0tLS18LS0tLS0tfAp8IDIwMThBICB8IDcuOSAgfCAyOC44IHwgMTYuNSB8CnwgMjAxOUEgIHwgOC44ICB8IDI5LjcgfCAxNi40IHwKfCAyMDIwQSAgfCA4LjYgIHwgMzAuMiB8IDE2LjMgfAp8IDIwMjFBICB8IDguNyAgfCAzMSAgIHwgMTYuOSB8CnwgMjAyMkEgIHwgNy45ICB8IDMxLjYgfCAxNy40IHwKfCAyMDIzRSAgfCA5LjggIHwgMzIuMiB8IDE3LjkgfAp8IDIwMjRFICB8IDEwLjUgfCAzMi44IHwgMTguMyB8CnwgMjAyNUUgIHwgMTEuMiB8IDMzLjIgfCAxOC43IHwKfCAyMDI2RSAgfCAxMiAgIHwgMzMuNiB8IDE5ICAgfAp8IDIwMjdFICB8IDEyLjcgfCAzMy45IHwgMTkuMiB8CnwgMjAyOEUgIHwgMTMuNSB8IDM0LjIgfCAxOS41IHwKfCAyMDI5RSAgfCAxNC4zIHwgMzQuNCB8IDE5LjYgfAp8IDIwMzBFICB8IDE1LjEgfCAzNC42IHwgMTkuOCB8CnwgMjAzMUUgIHwgMTUuNiB8IDM0LjYgfCAxOS44IHwKfCAyMDMyRSAgfCAxNi4xIHwgMzQuNSB8IDE5LjcgfAoKCiMjIyBUMkRN5oKj6ICF5Lq65pWw55qE6KGo5qC877yI5Y2V5L2N77ya55m+5LiH5ZCN5oKj6ICF77yJCgp8IOW5tOS7vSAgIHwg5Lit5Zu9IHwg576O5Zu9IHwg5qyn5rSyIHwKfC0tLS0tLS0tfC0tLS0tLXwtLS0tLS18LS0tLS0tfAp8IDIwMThBICB8IDExNS4xfCAzMC41IHwgNDguNyB8CnwgMjAxOUEgIHwgMTE2LjZ8IDMxLjEgfCA0OSAgIHwKfCAyMDIwQSAgfCAxMTguOXwgMzEuNSB8IDQ5LjQgfAp8IDIwMjFBICB8IDEyMSAgfCAzMS44IHwgNDkuNyB8CnwgMjAyMkEgIHwgMTIzLjJ8IDMyLjEgfCA1MC4xIHwKfCAyMDIzRSAgfCAxMjUuNHwgMzIuNCB8IDUwLjUgfAp8IDIwMjRFICB8IDEyNy42fCAzMi43IHwgNTAuOSB8CnwgMjAyNUUgIHwgMTI5Ljh8IDMzLjMgfCA1MS40IHwKfCAyMDI2RSAgfCAxMzIgIHwgMzMuNiB8IDUxLjcgfAp8IDIwMjdFICB8IDEzNC4xfCAzMy45IHwgNTIuMSB8CnwgMjAyOEUgIHwgMTM2LjN8IDM0LjEgfCA1Mi40IHwKfCAyMDI5RSAgfCAxMzguNHwgMzQuNCB8IDUyLjggfAp8IDIwMzBFICB8IDE0MC41fCAzNC41IHwgNTMuMiB8CnwgMjAzMUUgIHwgMTQxLjJ8IDM0LjUgfCA1My4yIHwKfCAyMDMyRSAgfCAxNDEuOHwgMzQuNyB8IDUzLjMgfAoKCiMjIyDotYTmlpnmnaXmupAgIArngbzor4blkqjor6I8fGVuZF9vZl9ib3h8Pg==
收藏
行业数据
2025-09-18
原图定位
查看详情
主要注射型GLP-1药物减重临床数据对比(非头对头,调整PBO,非T2DM人群)
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
收藏
行业数据
2025-09-18
原图定位
查看详情
礼来分别启动Orforglipron片剂针对肥胖(-T2DM/+T2DM)的两个全球III期临床
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
收藏
行业数据
2025-09-03
原图定位
查看详情
图23不同地区T2DM人群中的NAFLD患病率情况
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
收藏
行业数据
2025-08-25
原图定位
查看详情
2017-2028E中国颅内动脉粥样硬化性疾病介入
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
收藏
行业数据
2025-08-14
原图定位
查看详情
心血管病构成居民主要疾病死因(2021年)
fCDnlr7nl4XnsbvliKsgfCDlhpzmnZEgfCDln47luIIgfAp8LS0tLS0tLS0tLS18LS0tLS0tfC0tLS0tLXwKfCDlv4PooYDnrqHnl4UgICB8IDUwJSAgfCA1MCUgIHwKfCDmgbbmgKfogr/nmKQgICB8IDIwJSAgfCAyNSUgIHwKfCDlkbzlkLjns7vnu5/nlr7nl4UgfCAxMCUgIHwgMTAlICB8Cnwg5o2f5LykL+S4reavkiAgIHwgNSUgICB8IDUlICAgfAp8IOWFtuS7liAgICAgICB8IDE1JSAgfCAxMCUgIHwKCui1hOaWmeadpea6kO+8muOAiuS4reWbveW/g+ihgOeuoeeXheWBpeW6t+S4jueWvueXheaKpeWRiiAyMDIz44CL44CB5byA5rqQ6K+B5Yi456CU56m2
收藏
行业数据
2025-07-15
原图定位
查看详情
T2DM药物在美国、中国和欧洲市场的规
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
收藏
行业数据
2025-05-29
原图定位
查看详情
最新数据
全球全年龄段奶粉市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球酸奶及发酵乳制品市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球药用级益生菌市场规模(百万美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球益生菌膳食补充剂市场规模及增速
收藏
行业数据
2026-07-30
原图定位
查看详情
全球拥有AKK专利菌株的核心企业
收藏
行业数据
2026-07-30
原图定位
查看详情
减重适应症渗透率远低于 2 型糖尿病,不足 1%。根据诺和诺德,2025 年 GLP-1 类药物在全球 2 型糖尿病处方占比仅 7%,其中美国市场约 19%,欧洲及加拿大约 9%,新兴市场、中国、APAC 等国家和地区占比仅 3%。体重管理适应症方面,美国 1.1 亿肥胖人群中,仅不超过 200 万人在使用诺和诺德减重药物;而全球范围内肥胖症的疗法渗透率更低,9.3亿肥胖人群中仅约 400 万人正在接受减重药物治疗,渗透率不足 0.5%。
行业数据
原图定位
当前图表所属:
【国金证券】医药行业研究:GLP-1专题,产品迭代驱动市场扩容,关注靶点、剂型及联合疗法研发进展-251117(38页).pdf
2026年GLP-1行业报告:产品迭代驱动扩容,多靶点与口服剂型重塑格局
【国金证券】医药行业研究:GLP-1专题,产品迭代驱动市场扩容,关注靶点、剂型及联合疗法研发进展-251117
GLP-1类减重药物1-3年维持率约32%/15%/8%
1Q23-2Q25,司美/替尔泊肽减重适应症销售额占比提升至37%
下载图片或Excel,需升级至尊VIP会员或「预见者」VIP
立即去升级
客服
商务合作
小程序
服务号
回到顶部
折叠
微信扫码登录
微信扫码登录
双重福利,扫码领取!
关注公众号『三个皮匠报告』,免费领取报告
1.100+最新优质行业报告
2.每周免费精选报告分享
手机快捷登录
账号登录
记住密码
忘记密码?
验证即登录,未注册将自动创建账号
获取验证码
收不到验证码注意事项
登录代表您已阅读并同意
《三个皮匠服务条款》